Rani Therapeutics (RANI) Q3 2026 earnings summary

Executive summary

• RT-114 Phase 1a single-dose data showed oral bioavailability above 150% versus matched subcutaneous dosing; no serious adverse events or events attributed to the capsule were reported.

• The RaniPill platform entered the FDA Emerging Technology Program in October 2026; participation supports technical, manufacturing and regulatory discussions, but is not approval.

• Partnerships with Chugai, ProGen and PegBio support programs in rare disease, immunology and obesity.

Financial highlights

• Q3 contract revenue was $1.7M, all from Chugai, versus $0 in Q3 2025; 9M revenue was $5.1M versus $0.2M.

• Q3 operating expenses rose 50.6% YoY to $10.9M; operating loss was $9.2M versus $7.3M and net loss was $8.8M versus $7.9M.

• 9M net loss narrowed to $25.2M from $31.9M and operating loss narrowed to $26.4M from $29.8M; net loss attributable to Class A holders rose to $22.2M from $19.4M.

• Q3 stock-based compensation was $2.2M versus $2.3M.

Outlook and guidance

• Cash, cash equivalents and marketable securities of $45.3M at September 30, 2026 are expected to fund operations through at least end-2027 under the current operating plan.

• Operating losses and negative operating cash flows are expected to continue; substantial additional funding will be needed for development, clinical trials and manufacturing scale-up.

• RT-114 Phase 1a expansion data are expected by year-end 2026; Phase 1b repeat-dose data in patients with obesity are anticipated in 2027.